Back to Search
Start Over
The α7 nicotinic receptor silent agonist R-47 prevents and reverses paclitaxel-induced peripheral neuropathy in mice without tolerance or altering nicotine reward and withdrawal.
- Source :
-
Experimental Neurology . Oct2019, Vol. 320, pN.PAG-N.PAG. 1p. - Publication Year :
- 2019
-
Abstract
- Various antitumor drugs, including paclitaxel, frequently cause chemotherapy-induced peripheral neuropathy (CIPN) that can be sustained even after therapy has been completed. The current work was designed to evaluate R-47, an α7 nAChR silent agonist, in our mouse model of CIPN. R-47 was administered to male C57BL/6J mice prior to and during paclitaxel treatment. Additionally, we tested if R-47 would alter nicotine's reward and withdrawal effects. The H460 and A549 non-small cell lung cancer (NSCLC) cell lines were exposed to R-47 for 24–72 h, and tumor-bearing NSG mice received R-47 prior to and during paclitaxel treatment. R-47 prevents and reverses paclitaxel-induced mechanical hypersensitivity in mice in an α7 nAChR-dependent manner. No tolerance develops following repeated administration of R-47, and the drug lacks intrinsic rewarding effects. Additionally, R-47 neither changes the rewarding effect of nicotine in the Conditioned Place Preference test nor enhances mecamylamine-precipitated withdrawal. Furthermore, R-47 prevents paclitaxel-mediated loss of intraepidermal nerve fibers and morphological alterations of microglia in the spinal cord. Moreover, R-47 does not increase NSCLC cell viability, colony formation, or proliferation, and does not interfere with paclitaxel-induced growth arrest, DNA fragmentation, or apoptosis. Most importantly, R-47 does not increase the growth of A549 tumors or interfere with the antitumor activity of paclitaxel in tumor-bearing mice. These studies suggest that R-47 could be a viable and efficacious approach for the prevention and treatment of CIPN that would not interfere with the antitumor activity of paclitaxel or promote lung tumor growth. • α7 silent agonist R-47 is antinociceptive in mice. • R-47 suppresses paclitaxel-induced changes in spinal microglia morphology. • R-47 lacks rewarding effects but produces spontaneous pain relief in the CPP test. • R-47 does not precipitate nicotine physical and affective-like withdrawal symptoms. • R-47 does not enhance tumor growth nor impair paclitaxel's antitumor effects. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 00144886
- Volume :
- 320
- Database :
- Academic Search Index
- Journal :
- Experimental Neurology
- Publication Type :
- Academic Journal
- Accession number :
- 138151950
- Full Text :
- https://doi.org/10.1016/j.expneurol.2019.113010